U.S. markets open in 8 hours 3 minutes

Global Cord Blood Corporation (CO)

NYSE - NYSE Delayed Price. Currency in USD
Add to watchlist
5.38+0.02 (+0.37%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close5.36
Open5.45
Bid0.00 x 1200
Ask0.00 x 1000
Day's Range5.30 - 5.45
52 Week Range2.81 - 6.31
Volume301,908
Avg. Volume238,923
Market Cap653.944M
Beta (5Y Monthly)0.41
PE Ratio (TTM)8.85
EPS (TTM)0.61
Earnings DateJun 28, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 31, 2018
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Undervalued
65% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • PR Newswire

    Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results

    Global Cord Blood Corporation (NYSE: CO) (the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release unaudited financial results for the fourth quarter and full year fiscal 2021 on Monday, June 28, 2021, after the U.S. market close.

  • PR Newswire

    Global Cord Blood Corporation Announces Formation of a Special Committee to Evaluate Non-Binding Proposal

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that in response to the non-binding proposal letter dated March 2, 2021 received by the Company's Board of Directors (the "Board") from Alternate Ocean Investment Company Limited ("Alternate Ocean"), pursuant to which Alternate Ocean, acting on behalf of the fund (the "Acquirer") that it manages and/or advises, proposes to acquire all of the outstanding ordinary shares of the Company for US$5.00 per ordinary share in cash, subject to certain conditions. The Board has formed a special committee of independent directors who are not affiliated with Alternate Ocean (the "Special Committee") to evaluate such proposal. The Special Committee consists of Mr. Mark D. Chen, Dr. Ken Lu, Mr. Jack Chow and Mr. Jacky Cheng, each of whom currently serves as an independent director on the Board, with Mr. Chen serving as the chair of the Special Committee.

  • Global Cord Blood Corporation Announces Receipt of Unsolicited Non-Binding Acquisition Proposal
    PR Newswire

    Global Cord Blood Corporation Announces Receipt of Unsolicited Non-Binding Acquisition Proposal

    Global Cord Blood Corporation (NYSE: CO) ("GCBC" or the "Company"), China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that its board of directors (the "Board") has received a non-binding proposal letter from Alternate Ocean Investment Company Limited ("Alternate Ocean"), a wholly-owned subsidiary of Haitong International Securities Group Limited (Stock Code: 665.HK), pursuant to which Alternate Ocean, acting on behalf of certain funds and/or entities that it manages and/or advises, proposes to acquire all of the outstanding ordinary shares of the Company for US$5.00 per ordinary share in cash, subject to certain conditions.